MAM
ANIP icon

Martingale Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Martingale Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
30,741
+3,203
+12% +$257K 0.06% 341
2026
Q1 		$2.12M Buy
27,538
+4,050
+17% +$316K 0.05% 337
2025
Q4 		$1.85M Sell
23,488
-226
-1% -$19.6K 0.05% 330
2025
Q3 		$2.17M Sell
23,714
-400
-2% -$32.6K 0.05% 295
2025
Q2 		$1.57M Buy
24,114
+499
+2% +$32.5K 0.04% 356
2025
Q1 		$1.58M Sell
23,615
-2,562
-10% -$153K 0.04% 358
2024
Q4 		$1.45M Sell
26,177
-8,563
-25% -$492K 0.04% 387
2024
Q3 		$2.07M Buy
34,740
+13,719
+65% +$837K 0.05% 302
2024
Q2 		$1.34M Buy
21,021
+2,590
+14% +$168K 0.03% 388
2024
Q1 		$1.27M Buy
18,431
+1,411
+8% +$85.2K 0.03% 411
2023
Q4 		$938K Hold
17,020
– – 0.02% 464
2023
Q3 		$988K Sell
17,020
-1
-0% -$58 0.02% 437
2023
Q2 		$916K Buy
17,021
+800
+5% +$35.5K 0.02% 472
2023
Q1 		$644K Hold
16,221
– – 0.01% 555
2022
Q4 		$653K Buy
16,221
+295
+2% +$11.1K 0.01% 572
2022
Q3 		$513K Buy
15,926
+3,100
+24% +$106K 0.01% 617
2022
Q2 		$381K Buy
12,826
+2,517
+24% +$72.6K 0.01% 703
2022
Q1 		$290K Buy
10,309
+801
+8% +$29.9K ﹤0.01% 730
2021
Q4 		$439K Buy
+9,508
New +$409K 0.01% 674
2020
Q4 		– Sell
-23,809
Closed -$673K – 875
2020
Q3 		$673K Sell
23,809
-26,700
-53% -$795K 0.01% 735
2020
Q2 		$1.64M Sell
50,509
-4
-0% -$143 0.02% 592
2020
Q1 		$2.06M Buy
50,513
+10,301
+26% +$548K 0.03% 482
2019
Q4 		$2.48M Sell
40,212
-5,400
-12% -$358K 0.03% 545
2019
Q3 		$3.33M Buy
45,612
+3,001
+7% +$225K 0.03% 472
2019
Q2 		$3.5M Buy
42,611
+15,502
+57% +$1.1M 0.04% 465
2019
Q1 		$1.91M Buy
27,109
+3,800
+16% +$224K 0.02% 614
2018
Q4 		$1.05M Buy
+23,309
New +$1.22M 0.01% 706

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's ANIP Position: Q2 2026 in Review

Martingale Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 12% in Q2 2026, buying an estimated $257K and bringing the position to 30,741 shares worth $2.54M. The position accounts for 0.06% of the portfolio, ranked #341.

Martingale Asset Management first reported a position in ANIP in Q4 2018 and has held it in 27 quarters since. The position peaked at $3.5M in Q2 2019. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Martingale Asset Management held 30,741 shares of ANI Pharmaceuticals worth $2.54M as of Q2 2026.
  • Martingale Asset Management bought 3,203 ANI Pharmaceuticals shares in Q2 2026, an estimated $257K.
  • ANI Pharmaceuticals made up 0.06% of Martingale Asset Management's portfolio in Q2 2026, its #341 holding.
  • Martingale Asset Management first reported a position in ANI Pharmaceuticals in Q4 2018 and has held it in 27 quarters since.
  • Martingale Asset Management's ANI Pharmaceuticals position peaked at $3.5M in Q2 2019.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.